Business Wire

New subgroup analyses of CLEAR Outcomes data showed bempedoic acid reduced the risk of major adverse cardiovascular events across various patient groups

Share

Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced additional results from prespecified subgroup analyses of the Phase 3 CLEAR (Cholesterol Lowering via Bempedoic Acid, an ATP citrate lyase (ACL)-Inhibiting Regimen) Outcomes trial. The results, presented at the 92nd European Atherosclerosis Society (EAS) Congress 2024, add to the growing understanding of the efficacy of NILEMDO®▼ (bempedoic acid) for the reduction of cardiovascular (CV) risk among patients at high-risk of CV disease. Specifically, results were presented for the subgroups of patients with obesity*, with metabolic syndrome (MetS)**, and female patients.1-6

LDL-C reduction in obese patients

Among patients with obesity in the CLEAR Outcomes trial, bempedoic acid reduced low-density lipoprotein cholesterol (LDL-C) levelsby 22.5% and MACE-4 by 23% versus placebo, and was well-tolerated with a similar safety profile as reported in the overall CLEAR Outcomes population.1 This increased efficacy regarding MACE-4 compared to the overall CLEAR Outcomes population is likely due to the higher underlying risk of CV events in this patient group.1 This data was previously presented at the ACC conference in April 2024.

LDL-C reduction in patients with or without MetS

In the CLEAR Outcomes subgroup analysis of patients with or without MetS, treatment with bempedoic acid reduced the risk of MACE-4 to a similar extent. This demonstrates bempedoic acid’s suitability as an option for patients requiring lipid-lowering therapy irrespective of their MetS status.2 Furthermore, results showed a small but significant reduction in body weight for patients with MetS.2 Bempedoic acid did not lead to an increase in new-onset diabetes in patients with or without MetS.2 The safety profile was generally comparable between MetS status and treatment group, however, higher rates of hyperuricemia were observed in patients with MetS randomised to bempedoic acid.2

Similar efficacy and safety profile across genders

CV outcomes data in women are scarce. In the CLEAR Outcomes trial, 48% of participants were female (6,740/13,970), achieving a near-equal gender balance.3 In this prespecified subgroup analysis, results showed that bempedoic acid demonstrated similar efficacy in CV risk reduction, versus placebo, in both male and female patients.3 Furthermore, the overall incidence of adverse events did not differ meaningfully between male and female patients.3 This data was previously presented at the ACC conference in April 2024.

Data from these subgroup analyses are consistent with results from the main CLEAR Outcomes analysis, which showed a 13% reduction in the relative risk of major adverse cardiovascular events defined as a four-component composite of death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke or coronary revascularisation (MACE-4).7 Furthermore, the safety profile in all patient subgroups was in line with that of the overall trial population.1-6

“Both men and women with obesity and/or metabolic syndrome are at significant risk of future cardiovascular events. The results presented at the EAS Congress suggest that bempedoic acid isan effective treatment for a range of patient subgroups.” saidIoanna Gouni-Berthold, University of Cologne, Center for Endocrinology, Diabetes, and Preventive Medicine. “As clinicians, our priority is to reduce LDL-C levels to lower the risk of CV events. Combination therapy with bempedoic acid may be one way to address this issue.”

“Our goal at Daiichi Sankyo is to help protect people from cardiovascular disease. To achieve this, we are working to improve the understanding of CV risk among a range of patient subgroups – including female patients who have previously been underrepresented in clinical trials. The data presented today adds to the growing body of evidence that bempedoic acid can be used effectively to address and manage the CV risk of patients who typically present to doctors,” said Stefan Seyfried, Vice President Medical Affairs, Specialty Medicines, at Daiichi Sankyo Europe GmbH.

Results of the CLEAR Outcomes subgroup analyses were presented as two ePoster sessions and four posters at the EAS Congress 2024:

  • ePoster session: Bempedoic acid for prevention of cardiovascular events in patients with obesity: A CLEAR Outcomes subset analysis, by S Nicholls, et al.1
  • ePoster session: Bempedoic acid efficacy and safety in 7,597 non-diabetic patients, with and without metabolic syndrome, from the randomized, placebo-controlled CLEAR Outcomes Trial, by P Taub, et al.2
  • Poster: Characteristics and outcomes for statin-intolerant women receiving bempedoic acid in the CLEAR Outcomes trial, by L Cho, et al.3
  • Poster: Identification and characterisation of patients with statin intolerance in France, by F Schiele, et al.4
  • Poster: Lipid-lowering therapy use and LDL-C goal attainment in France: Results from 1-year follow-up of the European observational SANTORINI study, by R Allouche, et al.5
  • Poster: Simulation of ezetimibe and bempedoic acid effect on LDL-C goal attainment in statin-intolerant patients across Europe: the 1-year follow-up SANTORINI observational study, by M Farnier, et al.6

*Obesity defined as BMI ≥30 kg/m2

**Metabolic syndrome defined as the presence of 1 or more of the following criteria: triglycerides ≥150mg/dL; HDL-C <40mg/dL for men or <50mg/dL for women; history of hypertension or blood pressure ≥130/85mmHG; fasting plasma glucose ≥100mg/dL; body mass index (used as a proxy for waist circumference) >25kg/m2 and >30kg/m2 for Asian and non-Asian patents, respectively.

About bempedoic acid and its fixed-dose combination with ezetimibe

Bempedoic acid is a first-in-class, oral, once-daily treatment to lower cholesterol, and which can be combined with other oral treatments to help lower cholesterol even further.8,9 Bempedoic acid inhibits ATP citrate lyase (ACL), an enzyme which is involved in the production of cholesterol in the liver.10

Bempedoic acid acts on the well-known cholesterol synthesis pathway, upstream of the statin target in the liver, which allows additional LDL-C lowering when added to statin or other LDL-C-lowering therapies.11 Bempedoic acid is not activated in skeletal muscle.10

Bempedoic acid is indicated in adults with established or at high risk for atherosclerotic CV disease to reduce CV risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:8,12

  • in patients on a maximum tolerated dose of statin with or without ezetimibe or,8,12
  • alone or in combination with ezetimibe in patients who are statin-intolerant, or for whom a statin in contraindicated.8,12

Bempedoic acid is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:8,12

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a or,8,12
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.8,12

The fixed-dose combination NUSTENDI® combines two complementary ways of reducing cholesterol in a once-daily tablet. NUSTENDI® is a fixed-dose combination (FDC) tablet containing bempedoic acid (the active pharmaceutical ingredient in NILEMDO®) and ezetimibe.

Bempedoic acid / ezetimibe FDC is indicated in adults with established or at high risk for atherosclerotic CV disease to reduce CV risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:12,13

  • in patients on a maximum tolerated dose of statin and not adequately controlled with additional ezetimibe treatment or,12,13
  • in patients who are either statin-intolerant, or for whom a statin in contraindicated, and not adequately controlled with additional ezetimibe treatment or,12,13
  • in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets12,13

Bempedoic acid / ezetimibe FDC is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:12,13

  • in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe,12,13
  • alone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone,12,13
  • in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without statin.12,13

Daiichi Sankyo Europe has licensed exclusive commercialisation rights to bempedoic acid and its FDC with ezetimibe (marketed as NILEMDO®and NUSTENDI®) in the European Economic Area, UK, Turkey and Switzerland from Esperion and is the full Marketing Authorisation Holder in these territories.

About CLEAR Outcomes trial

The CLEAR Outcomes trial was a Phase 3, event-driven, randomised, multicentre, double-blind, placebo-controlled trial.14 It was designed to evaluate whether treatment with bempedoic acid, marketed as NILEMDO®▼ in Europe, reduced the risk of cardiovascular events in a mixed population of patients who had or were at high-risk for CVD, and for whom primary or secondary CVD prevention was clinically indicated but who were unable or unwilling to receive statin treatment.14

The trial, which was fully enrolled in August 2019, randomised 13,970 patients, aged 18–85 years of age with an average age of 65.5 years at 1,250 sites in 32 countries across the world including 485 sites in Europe.14 Patients had a mean LDL-C at baseline of 3.59 mmol/L (139.0 mg per decilitre) and were randomised to either treatment with bempedoic acid 180 mg daily or matching placebo on a background of guideline-directed medical therapy in both the bempedoic acid and placebo groups.7 Patients were followed up for a median duration of 40.6 months.7

The primary endpoint of the CLEAR Outcomes trial was a four-component composite of major adverse CV events (MACE-4) defined as death from CV causes, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularisation.14 Key secondary endpoints included: MACE-3, a composite of three major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke); fatal and nonfatal myocardial infarction; coronary revascularisation; fatal and non-fatal stroke; cardiovascular death; and all-cause mortality.14

About Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need.

For more information, please visit www.daiichisankyo.com

This medicinal product is subject to additional monitoring.

References

________________________
1 EAS 2024 ePoster. Bempedoic acid for prevention of cardiovascular events in patients with obesity: A CLEAR Outcomes subset analysis, by S Nicholls, et al.
2 EAS 2024 ePoster. Bempedoic acid efficacy and safety in 7,597 non-diabetic patients, with and without metabolic syndrome, from the randomized, placebo-controlled CLEAR Outcomes Trial, by P Taub, et al.
3 EAS 2024 Poster. Characteristics and outcomes for statin-intolerant women receiving bempedoic acid in the CLEAR Outcomes trial, by L Cho, et al.
4 EAS 2024 Poster. Identification and characterisation of patients with statin intolerance in France, by F Schiele, et al.
5 EAS 2024 Poster. Lipid-lowering therapy use and LDL-C goal attainment in France: Results from 1-year follow-up of the European observational SANTORINI study, by R Allouche, et al.
6 EAS 2024 Poster. Simulation of ezetimibe and bempedoic acid effect on LDL-C goal attainment in statin-intolerant patients across Europe: the 1-year follow-up SANTORINI observational study, by M Farnier, et al.
7 Nissen, S.E., et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023. 13;388;(15): 1353–1364.
8 European Medicines Agency. Nilemdo - opinion on variation to marketing authorisation. Available at: https://www.ema.europa.eu/en/medicines/human/variation/nilemdo. Last accessed May 2024.
9 The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020. 41;(1): 111–188.
10 European Medicines Agency. NilemdoSummary of Product Characteristics. May 2024. Available at: https://www.ema.europa.eu/en/documents/product-information/nilemdo-epar-product-information_en.pdf. Last accessed May 2024
11 Pinkosky, S.L., et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016. 7: 13457.
12 Daiichi Sankyo Europe GMBH. First-in-class cholesterol-lowering treatment NILEMDO®▼ and its combination with ezetimibe, NUSTENDI®▼, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk. Available at: https://www.businesswire.com/news/home/20240514593487/en/First-in-class-cholesterol-lowering-treatment-NILEMDO%C2%AE%E2%96%BC-and-its-combination-with-ezetimibe-NUSTENDI%C2%AE%E2%96%BC-approved-in-Europe-to-lower-LDL-cholesterol-and-reduce-cardiovascular-risk. Last accessed May 2024
13 European Medicines Agency. Nustendi - opinion on variation to marketing authorisation. Available at: https://www.ema.europa.eu/en/medicines/human/variation/nustendi. Last accessed May 2024.
14 Nicholls, S.J., et.al. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J. 2021. 235: 104–112.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Gillian D’Souza
Daiichi Sankyo Europe GmbH
Senior Manager, Public Relations, Specialty Medicines
+49 1515 5195599

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)15.2.2025 00:50:00 CET | Press Release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZA™ (vimseltinib), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. The FDA previously granted Fast Track designation and Priority Review for ROMVIMZA, which was developed by Deciphera Pharmaceuticals, Inc. (“Deciphera”), a wholly owned subsidiary of Ono. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250214768549/en/ “The approval of ROMVIMZA provides a new, much-needed, well-tolerated, and effective treatment option for people suffering from TGCT,” said Hans Gelderblom, M.D., Ph.D., Chair of the Department of Medical Oncology at Leiden University Medical Center. “TGCT adversely affects the lives of patients, ca

Venture Global, Inc. Announces Timing of Fourth Quarter and Full Year 2024 Earnings Release and Conference Call14.2.2025 19:17:00 CET | Press Release

Venture Global, Inc. (“Venture Global”)(NYSE: VG) announced today that it plans to issue its earnings release with respect to fourth quarter and full year 2024 financial results before market open on Thursday, March 6, 2025. Venture Global will host a conference call for investors and analysts beginning at 9:00 am Eastern Time (ET) on March 6, 2025, to discuss fourth quarter and full year results and provide guidance for the 2025 fiscal year. A listen-only webcast of the call and accompanying slide presentation will be available at Venture Global’s Investor Relations website HERE. After the conclusion of the webcast, a replay will be made available on the Venture Global website. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. Venture Global’s fir

Asa Gudmundsdottir Wright Award Presented as Plans for New Icelandic Academy of Science & Innovation Announced14.2.2025 17:35:00 CET | Press Release

Iceland’s President, Halla Tomasdottir, presented the Asa Gudmundsdottir Wright Award at a ceremony at the presidential residence. This year’s recipients are G. Fertram Sigurjonsson, Founder and CEO of Kerecis, and Jon Atli Benediktsson, Rector of the University of Iceland. The award honors individuals who have made significant contributions to science and innovation in Iceland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250214199674/en/ President Halla Tomasdottir and Kerecis Founder and CEO Fertram Sigurjonsson (Photo: Business Wire) During the ceremony, plans were also announced for the establishment of the Icelandic Academy of Science & Innovation, into which the award recipients will be inducted as members. The academy will provide a platform for collaboration between researchers, entrepreneurs, industry representatives, and academia. It will uphold the tradition of the Asa Fund by granting annual awards and aims to

Riskified To Report Fourth Quarter and Full-Year 2024 Financial Results on Wednesday, March 514.2.2025 17:33:00 CET | Press Release

Riskified Ltd. (NYSE: RSKD), a leader in ecommerce fraud and risk intelligence, today announced it will release its fourth quarter and full-year 2024 financial results before the market opens on March 5, 2025. On that day management will host a conference call and webcast at 8:30 a.m. ET to discuss the company's business and financial results. Riskified Fourth Quarter and Full-Year 2024 Financial Results Conference Call When: Wednesday, March 5, 2025 Time: 8:30 a.m. ET Dial-in: To access the conference call via telephone, please register via this registration link and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. Webcast: A live and archived webcast of the conference call will be accessible from the “Events & Presentations” section of the Company’s Investor Relations website at https://ir.riskified.com/. About Riskified Riskified (NYSE:RSKD) empowers businesses to

Elon Musk Talks ‘Tech Support’ Governance as World Leaders Champion Innovation-Driven Reforms at Dubai Summit14.2.2025 16:57:00 CET | Press Release

Wearing a “Tech Support”-printed T-shirt, Elon Musk virtually took to the stage on the final day of the World Governments Summit in a live discussion with H.E. Omar Sultan Al Olama, UAE Minister of State for Artificial Intelligence, Digital Economy, and Remote Work Applications, to share his vision for improving government efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250214293771/en/ Elon Musk in conversation with H.E. Omar Sultan Al Olama, UAE Minister of State for Artificial Intelligence, Digital Economy, and Remote Work Applications (Photo: Business Wire) Musk emphasized the urgency of streamlining operations, advocating for smaller, more accountable institutions to drive efficiency and economic growth. The World Governments Summit, held in Dubai from February 11-13, brought together global leaders and experts to address critical challenges in governance, healthcare, and trade in the 21st century. Now in its

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye